tirzepatide and semaglutide therapeutic modality vs dosage chart: complete comparison guide Tirzepatide on ingestive behavior in

Understanding the difference between research-grade and pharmaceutical-grade compounds is essential for anyone evaluating telehealth medication providers

If you are taking any GLP-1 medication and plan to switch to another one, always start the new medication at the lowest dose and titrate it gradually to minimize the risk of side effects

The human and mouse enteric nervous system at single-cell resolution

Mounjaro Lawsuits May Impact Growth of Eli Lilly Diet Drug Amid Stomach Paralysis Problems Although Eli Lillys recently introduced diet drug has seen rapid sales growth, a new Mounjaro lawsuit alleges that users are not adequately warned about gastrointestinal side effects that may cause stomach paralsysis Mounjaro was introduced in May 2022, as a weight loss drug for type 2 diabetes patients FDA now is reviewing the results of Mounjaro clinical trial data and could approve wider use of the drug specifically for weight loss by the end of 2023 Eli Lilly was recently hit with a Mounjaro lawsuit over stomach paralysis or gastroparesis Similar lawsuits may soon be filed by additional users, alleging drug maker failed to adequately disclose the potential Mounjaro side effects FIND OUT IF YOU QUALIFY FOR A MOUNJARO LAWSUIT As pharmaceutical giant Eli Lilly continues to seek official approval for the wider use of its potential blockbuster drug Mounjaro as a treatment for obesity in non-diabetic patients, a recently filed Mounjaro lawsuit may signal the start of a problem for the drug maker, as additional users contemplate filing claims after developing severe stomach paralysis or gastroparesis